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The ultimate goal for hematologists, cardi-
ologists, and vascular medicine physicians
is to find agents that prevent thrombosis
without creating defects in hemostasis (the
cessation of bleeding). To a great extent,
this notion was considered an impossible
dream. However, recent advances in under-
standing of the plasma contact activation,
kallikrein/kinin, renin angiotensin, and
other vasoregulatory systems make these
dreams seem feasible. Presently, all anti-
coagulants prevent thrombosis by inter-
fering with hemostasis. Physicians in clin-
ical medicine are presently excited with
the recent approvals by national regulatory
agencies of several target-specific oral anti-
coagulants (TSOACs). These agents make
the lives of patients who need anticoag-
ulants much easier. However, the targets
of the TSOACs, factors IIa and Xa, still
increase bleeding risk. In fact, some of these
agents are associated with specific organ
sensitivity to bleeding not seen with war-
farin or heparin-derived agents. Further-
more, although in late development, anti-
dotes to these agents are not present and
bleeding such as into the brain can be cata-
strophic. We can do better than the current
array of agents in practice and about to be
approved for clinical practice for throm-
bosis protection. In recent years, investiga-
tors have learned that many proteins influ-
ence thrombosis risk without altering the
hemostatic system. For example, proteins
like heme oxygenase, C-reactive protein,
glutathione peroxidase-3 deficiency, pep-
tidylarginine deiminase 4, and myeloid-
related protein-14 (S100A9) alter arterial
or venous thrombosis propensity in mice
without influence on hemostasis (1–5).
Additionally, there are several targets in the
contact activation (CAS), kallikrein/kinin
(KKS), and renin angiotensin (RAS) sys-
tems that influence thrombosis without
causing bleeding. Better understanding of
the mechanism(s) by which these proteins
influence venous and arterial thrombosis
may very well allow for additional targets to
be recognized for the development of safer
therapies. The next frontier in drug devel-
opment to prevent or treat thrombosis is to
translate the mechanistic observations on
proteins that alter thrombosis risk without
bleeding into therapeutic agents.
Where do we start on this endeavor?
It is already happening. For example, evi-
dence indicates that the proteins of the
plasma CAS and KKS [factor XII (XII),
prekallikrein (PK), high molecular weight
kininogen (HK)] influence thrombosis risk
even though it is well recognized that their
deficiencies in humans have no influence
on hemostasis. Factor XII, PK, HK, and
bradykinin B2 receptor-deleted mice are
protected from venous and arterial throm-
bosis (6–9). More complete understanding
of the mechanism of the thrombosis pro-
tection of the proteins of the CAS and KKS
in vivo should provide leads for novel tar-
gets for development of antithrombotics.
Contact activation is the process where
XII and to a lesser extent PK or factor XI
autoactivate into their enzymes on a sur-
face, usually negatively charged but can be
neutrally charged. Formed XIIa activates
PK to plasma kallikrein that then recipro-
cally activates XII and they amplify each
other’s activation leading to factor XI acti-
vation. It is the formation of factor XIa that
initiates hemostasis after XII activation.
The KKS is formed by plasma kallikrein
cleaving HK to liberate bradykinin. This
pathway initiates angioedema and inflam-
mation, not thrombosis. XII autoactivation
alone is a slow process but its rate of acti-
vation is markedly accelerated when HK
and PK are present. Amplification of XII
and PK activation when both are present
occurs very rapidly especially with HK
present. Contact activation occurs in vivo
when blood interacts with artificial sur-
faces such as an extracorporeal circulation
system, indwelling intravenous catheters,
infectious organisms, and adult respiratory
distress syndrome (10–13). All these states
lead to thrombin formation. C1 inhibitor
deficiency states or C1 inhibitor consump-
tion by a mutant factor XIIa activate the
KKS and lead to angioedema and inflam-
mation, not thrombin formation (14, 15).
If contact activation is prevented,
can thrombosis be thwarted? Antisense
oligonucleotides to XII, PK, and factor
XI prevent thrombosis in various arter-
ial and venous thrombosis models (16,
17). Factor XI is at times considered a
contact system protein because it is acti-
vated by XIIa. Reduction of factor XI by
50% reduces thrombosis risk in murine
and baboon models without excess bleed-
ing, but severe factor XI deficiency upon
injury is a bleeding state (17). Additionally,
a recent report by Renne and his asso-
ciates suggests that thrombosis prevention
by XIIa inhibition may be feasible on arti-
ficial surfaces such as that used in extracor-
poreal membrane oxygenation (18). These
investigators produced a very specific anti-
body (3F7) to activated factor XII (XIIa) by
phage display. This antibody only blocks
XIIa (αXIIa) or βXIIa (Hageman factor
fragment) interfering with PK or factor
XI activation. In an extracorporeal circu-
lation experiment with rabbits attached to
an infant’s membrane oxygenator, 3F7 was
nearly as good as unfractionated heparin to
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prevent d-dimer elevation, fibrinogen con-
sumption, prothrombin 1+ 2 fragments,
platelet consumption, and reduced pres-
sures in the circuit (18). Furthermore, it
did this without any increase in bleed-
ing. Thus, precise factor XIIa inhibition
alone is able to prevent thrombosis of
blood when coursing through an artifi-
cial circuit such as cardiopulmonary bypass
attached to an individual (19). Further-
more, such an agent needs no antidote
because its presence does not interfere
with tissue factor- and/or FXIa-induced
hemostasis. Thus, anticoagulation with-
out influence on bleeding is presently
achievable in situations where human tis-
sue and blood are exposed to artificial
surfaces such as cardiopulmonary bypass,
indwelling catheters, artificial hearts, and
other devices interfaced with the vascu-
lature. Can these observations be trans-
lated to other situations of pathophysio-
logic contact activation? An agent such as
3F7 also may reduce contact activation-
induced sepsis from any cause, ARDS, and
some attacks of hereditary angioedema.
Are there other instances whereby
interruption of thrombotic mechanisms
has potential to decrease arterial throm-
bosis risk without effect on hemosta-
sis? These possibilities exist, but fur-
ther development is needed. Recent stud-
ies from our laboratory have described
the bradykinin B2 receptor-deleted mouse
(Bdkrb2−/−) to be protected from throm-
bosis (9, 20). When we embarked upon
these studies, we had hypothesized that
Bdkrb2−/− mice would be prothrombotic
because bradykinin is a potent stimula-
tor of NO and prostacyclin production
and tPA liberation. When we examined
mechanism for thrombosis protection in
Bdkrb2−/− mice, we observed increased
plasma bradykinin, its breakdown prod-
uct bradykinin-(1–5), and angiotensin
II. Angiotensin-converting enzyme (kin-
inase II) degrades both bradykinin and
angiotensin I. Normally angiotensin II
binds to its receptor, the angiotensin recep-
tor 1, to induce vasoconstriction, elevation
of blood pressure, and increase thrombo-
sis propensity through expression of tissue
factor and plasminogen activator inhibitor.
However, we found in Bdkrb2−/− mice
that there also was increased expression
of the angiotensin receptor 2 (AT2R) that
scooped up the excess angiotensin II to
produce the dominant phenotype. Stim-
ulation of the AT2R results in elevated
NO and prostacyclin. In fact these animals
have a long bleeding time due to prosta-
cyclin elevation, not NO. If Bdkrb2−/−
mice are treated with an antagonist to
the AT2R, a cyclooxygenase inhibitor or
an eNOS antagonist, the bleeding and
thrombosis times shorten to normal. Thus,
higher angiotensin II in the presence of
increased expression AT2R has potential
as antithrombotic agents. AT2R elevation
lengthens thrombosis time in the presence
of excess angiotensin II (9, 20).
Most would agree that elevating
angiotensin II is not attractive as an
anticoagulant mechanism. If we treat
Bdkrb2−/− with losartan or telmisartan,
angiotensin receptor 1 antagonists, we
lower plasma angiotensin II levels with-
out correcting their prolonged thrombosis
time. These data suggest that there is an
additional thromboprotective mechanism
in Bdkrb2−/− mice. Further studies show
that the angiotensin II breakdown product,
angiotensin-(1–7) and its G-protein cou-
pled receptor Mas are also over-expressed
(20). If Bdkrb2−/− mice are treated with
a Mas antagonist, A-779, their thrombo-
sis times correct to normal. Bdkrb2−/−
mice have prostacyclin levels threefold nor-
mal and it is associated with long tail
bleeding times. These animals also have a
GPVI activation and an integrin spreading
defect. Recent preliminary studies in our
laboratory suggest that PK-deficient mice
(Klkb1−/−) have a similar mechanism for
thrombosis protection. These combined
data suggest that regulation of Mas expres-
sion and its influence on plasma prostacy-
clin levels may be sufficient for thrombosis
protection without influence on hemosta-
sis (21). Thus, regulating levels of expres-
sion of the receptor Mas alone may be
sufficient to modulate thrombosis risk.
Are there additional targets for
antithrombotic agent development? Pro-
lylcarboxy peptidase (PRCP) is a serine
protease that cleaves peptides when a pro-
line is in the penultimate position of the
carboxy terminus and activates PK. Its
peptide substrates include angiotensin II,
bradykinin-(1–8), and α-melanocyte stim-
ulating hormone 1–13 (α-MSH1–13). A
PRCP gene trap mouse (PRCPgt/gt) that
has ~25% PRCP levels is lean, hyper-
tensive, and has a propensity for arterial
thrombosis. The major mechanistic fea-
ture of this animal with a thrombosis
propensity is that there is increased reac-
tive oxygen species (ROS) in its vessels and
kidney. When treated with antioxidants,
the ROS lowering corrects the arterial
thrombosis time on two models to normal
(22). The consequence of increased ROS in
the vasculature of these animals is reduc-
tion of the vasoprotective transcription
factors Kruppel-like factors 2 and 4 leading
to reduced eNOS mRNA and uncoupled
NO and less thrombomodulin activity,
mRNA, and antigen. ROS oxidizes a crit-
ical methionine on thrombomodulin that
interferes with protein C activation. There
is also elevated tissue factor and PAI-1
in these vessels. These combined find-
ings alter vascular health. PRCP-deficient
cells and PRCPgt/gt mice have reduced cell
proliferation and migration, angiogenesis,
and wound repair with increased apop-
tosis (23). They have excessive vascular
inflammation after injury that is blocked
genetically by concurrent deletion of the
inflammatory protein, myeloid-related
protein 8–14 (S100A9) (5, 23). PRCP’s
growth factor domain that produces its
cell proliferation and migration and angio-
genesis to reduce ROS and apoptosis is
not the enzyme’s active site. These data
suggest that a vasculoprotective protein
region could be derived from PRCP and
utilized to promote vascular health, the
kind of which would reduce thrombosis
risk and its consequences. Thus, by having
well-characterized mechanistic studies on
animal models, we are able to tease out
new proteins that have potential to tar-
get development for new kinds of agents
to protect an organism from thrombosis
without anticoagulation.
Thus, there are several challenges we
should ask of investigators who develop
new antithrombotics. First is to find new
targets for agent development through
careful mechanistic investigations in in vivo
studies. It is clear that thrombosis risk is
a polygenic problem and focus only in the
classic hemostasis, anticoagulant, and fibri-
nolysis fields will develop agents that have
variable risk for hemostatic defects. How-
ever, these in vivo systems do not exist in
isolation and modifying genes and proteins
may prove better antithrombotics with less
or no bleeding risks. Additional challenges
to investigators are finding resources to
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develop novel ideas in a world where there
are decreasing funding for basic science
with a translational goal. Finally, a chal-
lenge needs to be sent to pharmaceuti-
cal companies whose decision makers are
inherently conservative and choose the
obvious for drug development programs
like all their competitors. It is very exciting
that one oral agent has been approved for
therapy venous thromboembolism in the
United States and three other agents have
been submitted for regulatory approval
within the last 6 months. Yet all these agents
have the same thrombin and factor Xa tar-
gets and all have a risk for interfering with
hemostasis while protecting from throm-
bosis. Like governmental funding agencies,
pharmaceutical companies need to expand
their research and development into novel
targets for thrombosis protection with-
out bleeding risk. Developing these pro-
grams is the real challenge for the coming
decade.
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